Quantcast

Reportlinker Adds U.S. Markets for Addiction and Substance Abuse Treatment Report

September 3, 2009

NEW YORK, Sept. 3 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

U.S. Markets for Addiction and Substance Abuse Treatment

http://www.reportlinker.com/p0109210/US-Markets-for-Addiction-and-Substance-Abuse-Treatment.html

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report details the complicated world of substance abuse. The increased prevalence of substance abuse poses a threat to the health and welfare of many populations throughout the world. Recreational drugs play a major role in crime and corruption and are becoming a larger problem each year. Abuse of prescription drugs and alcohol places a heavy burden on health resources due to the subsequent medical problems. Breaking the substance abuse cycle is a difficult and tedious process. Pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. Those products are detailed in the report. Also discussed are the products to help employers, parents, social workers, and other groups and organizations detect for substance abuse.

The objectives of the study are to heighten the awareness of drug abuse and to identify preparations, tests, and important advancements in the drug abuse treatment arena. The study analyzes the new therapeutics and diagnostics for drug abuse treatment from a current standpoint as well as what is on the horizon. Manufacturers of pharmaceutical products have been reluctant to invest valuable time and resources into this market because of the issues facing the market. As a result, the problem of drug abuse continues to grow.

REASONS FOR DOING THE STUDY

This BCC study is presented to increase the awareness of substance abuse and identify pharmaceutical preparations that are used to treat addictions.

INTENDED AUDIENCE

Because of the evolving nature of this important area of medicine, executives of substance abuse pharmaceuticals must remain ever vigilant to the changing environment and strive to keep abreast of new and currently used modalities in all facets of substance abuse treatment

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: EXECUTIVE SUMMARY

SUMMARY TABLE U.S. MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)

SUMMARY FIGURE U.S. MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)

CHAPTER THREE: INDUSTRY OVERVIEW

HISTORY OF SUBSTANCE ABUSE

OVERVIEW OF SUBSTANCE ABUSE

OVERVIEW OF SUBSTANCE ABUSE (CONTINUED)

MODELS OF ADDICTION

ADDICTION THEORIES

Biological Theories

Psychological Theories

Sociocultural Theories

PATTERNS OF SUBSTANCE ABUSE

RISK FACTORS

ADDICTIVE PROCESS

DEMOGRAPHIC TRENDS

TABLE 1 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)

FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)

TABLE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)

FIGURE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)

TOBACCO USE

FIGURE 3 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF TOBACCO USE, 2005 (MILLION PEOPLE)

Age

FIGURE 4 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER, 2005 (%)

Gender

FIGURE 5 PAST MONTH OF TOBACCO USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)

Race/Ethnicity

FIGURE 6 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)

Education

FIGURE 7 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2006 (%)

College Students

FIGURE 8 PAST MONTH OF TOBACCO USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18 TO 22, ESTIMATED, 2006 (%)

Employment

FIGURE 9 PAST MONTH OF TOBACCO BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2006 (%)

Geographic Area

FIGURE 10 PAST MONTH OF TOBACCO USE BY GEOGRAPHIC REGION BASED ON POPULATION DENSITY FOR AGES 12 OR OLDER, ESTIMATED, 2006 (%)

Association of Tobacco Use with Illicit Drug and Alcohol

Use

FIGURE 11 PAST MONTH ILLICIT DRUG, ALCOHOL USE AMONG SMOKERS AND NONSMOKERS AGED 12 OR OLDER, ESTIMATED 2006 (%)

ALCOHOL USE

FIGURE 12 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY DRINKING STATUS: UNITED STATES, 1997 AND 2006 (%)

Alcohol Frequency

FIGURE 13 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY FREQUENCY: UNITED STATES, 2002-2005 (%)

Age

FIGURE 14 PAST MONTH ALCOHOL USE AMONG PERSONS BY AGE, 2005 (%)

Gender

FIGURE 15 PAST MONTH ALCOHOL USE FOR MALES AND FEMALES AGE 12 OR OLDER, 2005 (%)

Pregnant Women

FIGURE 16 PAST MONTH OF ALCOHOL USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED 2002-2007 (%)

Race/Ethnicity

FIGURE 17 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)

Education

FIGURE 18 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 (%)

College Students

FIGURE 19 PAST MONTH ALCOHOL USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2002 AND 2006 (%)

Employment

FIGURE 20 PAST MONTH ALCOHOL USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)

Geographic Area

FIGURE 21 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY UNITED STATES GEOGRAPHIC REGION, 1997 AND 2006 (%)

Driving Under the Influence of Alcohol

FIGURE 22 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ALCOHOL, AGES 12 OR OLDER, ESTIMATED, 2005 AND 2006 (%)

ILLICIT DRUG USE

FIGURE 23 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF DRUG: UNITED STATES, 2002-2005 (%)

FIGURE 23 (CONTINUED)

Age

FIGURE 24 PAST MONTH ILLICIT DRUG USE BY AGE, 2005 (%)

Gender

FIGURE 25 PAST MONTH ILLICIT DRUG USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)

Pregnant Women

FIGURE 26 PAST MONTH ILLICIT DRUG USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED, 2005-2006 (%)

Race/Ethnicity

FIGURE 27 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, ESTIMATED, 2005

Education

FIGURE 28 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006

College Students

FIGURE 29 PAST MONTH ILLICIT DRUG USE BY ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2005-2006 (%)

Employment

FIGURE 30 PAST MONTH ILLICIT DRUG USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)

Geographic Area

FIGURE 31 PAST MONTH ILLICIT DRUG USE FOR GEOGRAPHIC REGION BASED ON POPULATION DENSITY AGES 12 OR OLDER, ESTIMATED, 2005-2006 (%)

Criminal Justice Populations

FIGURE 32 PAST YEAR ILLICIT DRUG USE BY PAROLE AND PROBATION STATUS AGED 18 OR OLDER, ESTIMATED, 2005-2006 (%)

Frequency of Use

Association with Cigarette and Alcohol Use

FIGURE 33 PAST MONTH ALCOHOL AND TOBACCO USE AMONG ILLICIT DRUG USERS AND NON ILLICIT DRUG USERS AGED 12 OR OLDER, ESTIMATED, 2005-2006

Driving Under the Influence of Illicit Drugs

FIGURE 34 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ILLICIT DRUGS, AGES 12 OR OLDER, ESTIMATED, 2005-2006 (MILLIONS)

ADDICTION TREATMENT COSTS SHIFTING

MANAGED CARE IMPACT

PARITY LAW

REIMBURSEMENT ISSUES

TABLE 3 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY, MARCH 31, 2006 (PERCENT DISTRIBUTION)

TABLE 4 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY: MARCH 31, 2006 (PERCENT DISTRIBUTION)

ECONOMIC COSTS OF SUBSTANCE ABUSE

TABLE 5 COMPARISON OF COSTS OF MAJOR HEALTH PROBLEMS IN U.S. ($ BILLIONS)

TABLE 6 ECONOMIC COSTS TO SOCIETY OF DRUG ABUSE 1992-2002 ($ MILLIONS)

STUMBLING BLOCKS TO DRUG ABUSE TREATMENT

NEW AVENUES FOR TREATMENT OF SUBSTANCE ABUSE

TABLE 7 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE–ALCOHOL, COCAINE, MARIJUANA AND HEROIN

TABLE 7 (CONTINUED)

TABLE 8 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE–OTHER OPIATES, PCPS, HALUCINOGENS, AMPHETAMINES, OTHER STIMULANTS, AND TRANQUILIZERS

TABLE 8 (CONTINUED)

TABLE 9 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE–SEDATIVES, INHALANTS, AND OTHER

TABLE 9 (CONTINUED)

TABLE 10 USE OF SUBSTANCES BY AMONG PERSONS AGED 50 OR OLDER, ESTIMATED 1999 AND PROJECTED 2020 BY GENDER, RACE, AND AGE GROUP, 1999

TABLE 11 USE OF SUBSTANCES BY PERSONS AGED 50 OR OLDER, BY GENDER, RACE, AND AGE GROUP, 2020

REGULATORY ISSUES

EFFECTS OF POLY DRUG ABUSE

POLYDRUG USE BY AGE

TABLE 12 ADMISSIONS REPORTING POLYDRUG ABUSE, BY AGE GROUP, 2002

PRIMARY AND SECONDARY USE

THE UNINSURED

TABLE 13 TOP 10 PRINCIPAL DIAGNOSES IN U.S. HOSPITALS WHICH HAVE UNINSURED RATES, 2002

TREATMENT FACILITIES AND PROGRAMS

OWNERSHIP OF SUBSTANCE ABUSE FACILITIES

TABLE 14 FACILITY OPERATION: NUMBER AND PERCENT DISTRIBUTION, 2002-2006

TREATMENT COSTS

TABLE 15 ESTIMATED TOTAL COSTS FOR SUBSTANCE ABUSE TREATMENT AND COST PER ADMISSION, BY TYPE OF CARE: 1997 (INFLATED TO 2002 COST LEVELS)

RESIDENTIAL REHABILITATION PATTERNS

Culture

Antabuse

Basic Methods

SELF-HELP GROUPS

TABLE 16 PERCENT DISTRIBUTION OF PERSONS AGED 12 OR OLDER WHO ATTENDED A “SELF-HELP” GROUP IN THE PAST YEAR BECAUSE OF THEIR ALCOHOL OR ILLICIT DRUG USE AND OF TOTAL POPULATION AGED 12 & OLDER, BY SOCIODEMOGRAPHIC CHARACTERISTICS: 2006 AND 2007

TABLE 16 (CONTINUED)

FIGURE 35 PERCENTAGES OF PAST YEAR SELF-HELP GROUP ATTENDEES AGED 12 OR OLDER, BY SUBSTANCE(S) FOR WHICH THEY ATTENDED A “SELF-HELP” GROUP, 2006 AND 2007 (%)

FIGURE 35 (CONTINUED)

NATIONAL PROGRAMS FOR SUBSTANCE ABUSE

BARRIERS TO MARKET ENTRY

NONACCEPTANCE OF MEDICAL MODELS OF ADDICTION

CHAPTER FOUR: PHARMACEUTICAL PRODUCTS

STIMULANTS

NICOTINE

Characteristics

Effects of Use

Complications

Therapeutic Management

TABLE 17 SMOKING CESSATION PRODUCTS

Therapeutic Management (Continued)

AMPHETAMINES

Characteristics

Effects of Use

Complications

Therapeutic Management

TABLE 18 AMPHETAMINE ABUSE TREATMENTS

COCAINE AND CRACK

Characteristics

Effects of Use

Complications

Therapeutic Management

TABLE 19 COCAINE ABUSE TREATMENTS

OTHER STIMULANTS

DEPRESSANTS

SEDATIVES-HYPNOTICS

Characteristics

Effects of Use

Complications

Therapeutic Management

ALCOHOL

Characteristics

Effects of Use

Complications

Complications (Continued)

Therapeutic Management

TABLE 20 ALCOHOL ABUSE TREATMENTS

OPIATES

Characteristics

Effects of Use

Complications

Therapeutic Management

Methadone

Other Products

Other Products (Continued)

TABLE 21 OPIATE ABUSE TREATMENTS

HALLUCINOGENS

CANNABIS

Characteristics

Effects of Use

Complications

Therapeutic Management

LYSERGIC ACID DIETHYLAMIDE, DIMETHYLTRYPTAMINE, MESCALINE, AND RELATED SUBSTANCES

Characteristics

Characteristics (Continued)

Effects of Use

Therapeutic Management

OTHER HALLUCINOGENS

INHALANTS AND OTHER DRUGS OF ABUSE

Gases, Solvents and Nitrites

Gases, Solvents . . . (Continued)

Anabolic Steroids

DIAGNOSTIC TESTING

URINE TESTING

SALIVA TESTING

BLOOD TESTING

PATCH TESTING

HAIR TESTING

SAMHSA POSITIVE DRUG TEST GUIDELINES

TABLE 22 POSITIVE DRUG TEST GUIDELINES (NG/ML)

DRUG TESTING INDEXES

TABLE 23 ANNUAL POSITIVITY RATES FOR U.S. WORKERS, BY YEAR 1988-2004 (%)

TABLE 24 POSITIVITY RATES FOR U.S. WORKERS BY TESTING REASON, 2000-2004

TABLE 25 POSITIVITY RATES FOR U.S. WORKERS BY DRUG CATEGORY AS A PERCENTAGE OF ALL POSITIVE TESTS (%)

TABLE 25 (CONTINUED)

POINT-OF-CARE SUBSTANCE ABUSE DIAGNOSTIC TESTING

Tobacco Testing

TABLE 26 POINT-OF-CARE NICOTINE DIAGNOSTIC TEST PRODUCTS

Jant Pharmacal

Nymox Pharmaceuticals

Princeton BioMeditech Corporation

Alcohol Testing

TABLE 27 POINT OF CARE ALCOHOL DIAGNOSTIC TEST PRODUCTS

Jant Pharmacal

MEDTOX Scientific, Inc.

OraSure Technologies

Princeton BioMeditech Corporation

Varian, Inc

Drug Testing

TABLE 28 POINT-OF-CARE DRUG DIAGNOSTIC TESTING PRODUCTS

Alfa Scientific Designs

American Bio Medica

BioScan Screening Systems

Biosite Diagnostics

Inverness Medical

MEDTOX Scientific, Inc.

OraSure Technologies

Phamatech

Princeton BioMeditech

Psychemedics Corp.

Varian, Inc

Sun Biomedical

HOME SUBSTANCE ABUSE DIAGNOSTIC TESTING

Alcohol Testing

TABLE 29 ALCOHOL HOME DIAGNOSTIC TESTING PRODUCTS

Jant Pharmacal

Sun Biomedical Laboratories

Drug Testing

TABLE 30 DRUG HOME DIAGNOSTIC TESTING PRODUCTS

Psychemedics

Dr. Brown’s (Elan Corporation)

Inverness Medical Innovations, Inc.

Phamatech

Princeton BioMeditech

Psychemedics

Sun Biomedical Laboratories

Sun Biomedical . . . (Continued)

CHAPTER FIVE: MARKET SIZE AND GROWTH

MARKET SIZE AND GROWTH

TABLE 31 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)

FIGURE 36 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)

PRESCRIPTION AND OVER-THE-COUNTER PHARMACEUTICAL TREATMENTS

SMOKING CESSATION

DRUG AND ALCOHOL ABUSE

TABLE 32 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)

FIGURE 37 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)

DIAGNOSTIC TESTING

POINT-OF-CARE TESTING

HOME TESTING

TABLE 33 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)

FIGURE 38 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, 2006-2013 ($ MILLIONS)

CHAPTER SIX: RESEARCH AND DEVELOPMENT

GOALS

AREAS OF CONCENTRATION

INDUSTRY NEEDS

CURRENT DRUGS IN CLINICAL TRIALS

ALCOHOL TREATMENT

OPIATE TREATMENT

GENERAL ADDICTION

TOBACCO TREATMENT

TABLE 34 SUBSTANCE ABUSE PRODUCTS IN DEVELOPMENT

TABLE 34 (CONTINUED)

MISCELLANEOUS SUBSTANCE ABUSE TREATMENT DISCOVERIES

MISCELLANEOUS SUBSTANCE ABUSE . . .(CONTINUED)

MISCELLANEOUS SUBSTANCE ABUSE . . .(CONTINUED)

CHAPTER SEVEN: INDUSTRY STRUCTURE

MARKET LEADERS

PFIZER

RECKITT BENCKISER

GLAXOSMITHKLINE

NOVARTIS

PSYCHEMEDICS

ORASURE TECHNOLOGIES

TABLE 35 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007

FIGURE 39 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 (%)

TABLE 36 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007

FIGURE 40 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 (%)

INDUSTRY PARTICIPANTS BY PRODUCT TYPE

TABLE 37 LEADING SUBSTANCE ABUSE PHARMACEUTICAL TREATMENT AND DIAGNOSTIC TESTING MANUFACTURERS BY PRODUCT TYPE, 2008

TABLE 37 (CONTINUED)

MARKET ANALYSIS

Anti-Depressant Market

Additional Therapies

Opportunities

Opportunities (Continued)

CHAPTER EIGHT: COMPANY PROFILES

GLAXOSMITHKLINE PLC

HISTORY

NOVARTIS PHARMACEUTICALS CORP.

HISTORY

ORASURE TECHNOLOGIES

HISTORY

PFIZER, INC

HISTORY

PHAMATECH, INC.

HISTORY

PSYCHEMEDICS CORP

HISTORY

RECKITT BENCKISER PLC

HISTORY

APPENDIX A–LIST OF COMPANIES

ABBOT DIAGNOSTICS

ABBOTT LABORATORIES

ALFA SCIENTIFIC DESIGNS, INC

ALKERMES, INC.

AMERICAN BIO MEDICA CORPORATION

ARADIGM CORPORATION

BARR LABORATORIES, INC

BIOSCAN SCREENING SYSTEMS, INC.

BIOSITE, INC.

BIOVAIL CORPORATION

BRISTOL-MYERS SQUIBB COMPANY

CARY PHARMACEUTICALS, INC.

CELTIC PHARMA MANAGEMENT L.P.

CEPHALON, INC.

CYTOS BIOTECHNOLOGY AG

DRUG ENFORCEMENT ADMINISTRATION

ELAN CORPORATION, PLC

ELBION NV

ELI LILLY & COMPANY

ENDO PHARMACEUTICALS

FOOD AND DRUG ADMINISTRATION

FOREST LABORATORIES, INC.

GLAXOSMITHKLINE PLC

INVERNESS MEDICAL INNOVATIONS, INC

JANT PHARMACAL CORPORATION

JOHNSON & JOHNSON

JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO)

MALLINCKRODT

MEDTOX SCIENTIFIC, INC.

NABI BIOPHARMACEUTICALS

NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM

NATIONAL INSTITUTE ON DRUG ABUSE

NOVARTIS INTERNATIONAL AG

NOVARTIS PHARMACEUTICALS CORP.

NYMOX PHARMACEUTICAL CORP.

OFFICE OF NATIONAL DRUG CONTROL POLICY

ORASURE TECHNOLOGIES, INC

OVATION PHARMACEUTICALS, INC

PFIZER, INC

PHAMATECH, INC.

PLIVA, INC.

PRINCETON BIOMEDITECH CORP.

PSYCHEMEDICS CORPORATION

PURDUE PHARMA, L.P.

RECKITT-BENCKISER PLC

ROCHE

SANOFI-AVENTIS

SOMAXONE PHARMACEUTICALS, INC

SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA)

SUN BIOMEDICAL LABORATORIES, INC.

TITAN PHARMACEUTICALS, INC

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

VALEANT PHARMACEUTICALS INTERNATIONAL

VARIAN, INC

XANODYNE PHARMACEUTICALS, INC

APPENDIX B–LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES

TABLE 38 LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 83 (CONTINUED)

TABLE 83 (CONTINUED)

LIST OF TABLES

SUMMARY TABLE U.S. MARKET FOR ADDICTION AND SUBSTANCE

ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013

($ MILLIONS)

TABLE 1 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)

TABLE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)

TABLE 3 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY, MARCH 31, 2006 (PERCENT DISTRIBUTION)

TABLE 4 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY: MARCH 31, 2006 (PERCENT DISTRIBUTION)

TABLE 5 COMPARISON OF COSTS OF MAJOR HEALTH PROBLEMS IN U.S. ($ BILLIONS)

TABLE 6 ECONOMIC COSTS TO SOCIETY OF DRUG ABUSE 1992-2002 ($ MILLIONS)

TABLE 7 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE–ALCOHOL, COCAINE, MARIJUANA AND HEROIN

TABLE 8 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE–OTHER OPIATES, PCPS, HALUCINOGENS, AMPHETAMINES, OTHER STIMULANTS, AND TRANQUILIZERS

TABLE 9 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE–SEDATIVES, INHALANTS, AND OTHER

TABLE 10 USE OF SUBSTANCES BY AMONG PERSONS AGED 50 OR OLDER, ESTIMATED 1999 AND PROJECTED 2020 BY GENDER, RACE, AND AGE GROUP, 1999

TABLE 11 USE OF SUBSTANCES BY PERSONS AGED 50 OR OLDER, BY GENDER, RACE, AND AGE GROUP, 2020

TABLE 12 ADMISSIONS REPORTING POLYDRUG ABUSE, BY AGE GROUP, 2002

TABLE 13 TOP 10 PRINCIPAL DIAGNOSES IN U.S. HOSPITALS WHICH HAVE UNINSURED RATES, 2002

TABLE 14 FACILITY OPERATION: NUMBER AND PERCENT DISTRIBUTION, 2002-2006

TABLE 15 ESTIMATED TOTAL COSTS FOR SUBSTANCE ABUSE TREATMENT AND COST PER ADMISSION, BY TYPE OF CARE: 1997 (INFLATED TO 2002 COST LEVELS)

TABLE 16 PERCENT DISTRIBUTION OF PERSONS AGED 12 OR OLDER WHO ATTENDED A “SELF-HELP” GROUP IN THE PAST YEAR BECAUSE OF THEIR ALCOHOL OR ILLICIT DRUG USE AND OF TOTAL POPULATION AGED 12 & OLDER, BY SOCIODEMOGRAPHIC CHARACTERISTICS: 2006 AND 2007

TABLE 17 SMOKING CESSATION PRODUCTS

TABLE 18 AMPHETAMINE ABUSE TREATMENTS

TABLE 19 COCAINE ABUSE TREATMENTS

TABLE 20 ALCOHOL ABUSE TREATMENTS

TABLE 21 OPIATE ABUSE TREATMENTS

TABLE 22 POSITIVE DRUG TEST GUIDELINES (NG/ML)

TABLE 23 ANNUAL POSITIVITY RATES FOR U.S. WORKERS, BY YEAR 1988-2004 (%)

TABLE 24 POSITIVITY RATES FOR U.S. WORKERS BY TESTING REASON, 2000-2004

TABLE 25 POSITIVITY RATES FOR U.S. WORKERS BY DRUG CATEGORY AS A PERCENTAGE OF ALL POSITIVE TESTS (%)

TABLE 26 POINT-OF-CARE NICOTINE DIAGNOSTIC TEST PRODUCTS

TABLE 27 POINT OF CARE ALCOHOL DIAGNOSTIC TEST PRODUCTS

TABLE 28 POINT-OF-CARE DRUG DIAGNOSTIC TESTING PRODUCTS

TABLE 29 ALCOHOL HOME DIAGNOSTIC TESTING PRODUCTS

TABLE 30 DRUG HOME DIAGNOSTIC TESTING PRODUCTS

TABLE 31 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE

ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)

TABLE 32 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)

TABLE 33 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)

TABLE 34 SUBSTANCE ABUSE PRODUCTS IN DEVELOPMENT

TABLE 35 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007

TABLE 36 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007

TABLE 37 LEADING SUBSTANCE ABUSE PHARMACEUTICAL TREATMENT AND DIAGNOSTIC TESTING MANUFACTURERS BY PRODUCT TYPE, 2008

TABLE 38 LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES

LIST OF FIGURES

SUMMARY FIGURE U.S. MARKET FOR ADDICTION AND SUBSTANCE

ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)

FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)

FIGURE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)

FIGURE 3 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF TOBACCO USE, 2005 (MILLION PEOPLE)

FIGURE 4 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER, 2005 (%)

FIGURE 5 PAST MONTH OF TOBACCO USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)

FIGURE 6 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)

FIGURE 7 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2006 (%)

FIGURE 8 PAST MONTH OF TOBACCO USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18 TO 22, ESTIMATED, 2006 (%)

FIGURE 9 PAST MONTH OF TOBACCO BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2006 (%)

FIGURE 10 PAST MONTH OF TOBACCO USE BY GEOGRAPHIC REGION BASED ON POPULATION DENSITY FOR AGES 12 OR OLDER, ESTIMATED, 2006 (%)

FIGURE 11 PAST MONTH ILLICIT DRUG, ALCOHOL USE AMONG SMOKERS AND NONSMOKERS AGED 12 OR OLDER, ESTIMATED 2006 (%)

FIGURE 12 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY DRINKING STATUS: UNITED STATES, 1997 AND 2006 (%)

FIGURE 13 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY FREQUENCY: UNITED STATES, 2002-2005 (%)

FIGURE 14 PAST MONTH ALCOHOL USE AMONG PERSONS BY AGE, 2005 (%)

FIGURE 15 PAST MONTH ALCOHOL USE FOR MALES AND FEMALES AGE 12 OR OLDER, 2005 (%)

FIGURE 16 PAST MONTH OF ALCOHOL USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED 2002-2007 (%)

FIGURE 17 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)

FIGURE 18 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 (%)

FIGURE 19 PAST MONTH ALCOHOL USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2002 AND 2006 (%)

FIGURE 20 PAST MONTH ALCOHOL USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)

FIGURE 21 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY UNITED STATES GEOGRAPHIC REGION, 1997 AND 2006 (%)

FIGURE 22 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ALCOHOL, AGES 12 OR OLDER, ESTIMATED, 2005 AND 2006 (%)

FIGURE 23 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF DRUG: UNITED STATES 2002-2005 (%)

FIGURE 24 PAST MONTH ILLICIT DRUG USE BY AGE, 2005 (%)

FIGURE 25 PAST MONTH ILLICIT DRUG USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)

FIGURE 26 PAST MONTH ILLICIT DRUG USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED, 2005-2006 (%)

FIGURE 27 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, ESTIMATED, 2005

FIGURE 28 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006

FIGURE 29 PAST MONTH ILLICIT DRUG USE BY ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2005- 2006 (%)

FIGURE 30 PAST MONTH ILLICIT DRUG USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)

FIGURE 31 PAST MONTH ILLICIT DRUG USE FOR GEOGRAPHIC REGION BASED ON POPULATION DENSITY AGES 12 OR OLDER, ESTIMATED, 2005-2006 (%)

FIGURE 32 PAST YEAR ILLICIT DRUG USE BY PAROLE AND PROBATION STATUS AGED 18 OR OLDER, ESTIMATED, 2005-2006 (%)

FIGURE 33 PAST MONTH ALCOHOL AND TOBACCO USE AMONG ILLICIT DRUG USERS AND NON ILLICIT DRUG USERS AGED 12 OR OLDER, ESTIMATED, 2005-2006

FIGURE 34 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ILLICIT DRUGS, AGES 12 OR OLDER, ESTIMATED, 2005-2006 (MILLIONS)

FIGURE 35 PERCENTAGES OF PAST YEAR SELF-HELP GROUP ATTENDEES AGED 12 OR OLDER, BY SUBSTANCE(S) FOR WHICH THEY ATTENDED A “SELF-HELP” GROUP, 2006 AND 2007 (%)

FIGURE 36 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS) FIGURE 37 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)

FIGURE 38 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, 2006-2013 ($ MILLIONS)

FIGURE 39 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 (%)

FIGURE 40 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 (%)

To order this report:

U.S. Markets for Addiction and Substance Abuse Treatment

http://www.reportlinker.com/p0109210/US-Markets-for-Addiction-and-Substance-Abuse-Treatment.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus